Category Archives: Pharmaceuticals

Glaxo dodges another Advair punch as second generic attempt crashes; Big Pharma’s plight highlights new world order for competition and innovation






The News: GlaxoSmithKline PLC is likely to escape generic competition to its blockbuster lung drug Advair in the US this year, after a second application for a cut-price equivalent form… Read more »

Merck’s Keytruda gets chemo-combo approval for lung cancer; science, stars align for multi-billion medicine






The News: Merck & Co. announced Wednesday (May 10, 2017) that the FDA awarded accelerated approval to Keytruda (pembrolizumab), in combination with Eli Lilly & Co.’s chemotherapy regimen Alimta (pemetrexed)… Read more »

Why Aeterna Zentaris got crushed, and is there any positive takeaway?






The News: Aeterna Zentaris Inc. (Nasdaq: AEZS) plunged 73% to $0.89 last week after announcing that the ZoptEC Phase 3 clinical study of Zoptrex (zoptarelin doxorubicin) in women with locally advanced,… Read more »

Week’s opening stock salvo: Cleveland BioLabs, ImmunoGen lead winners; XBiotech, OncoMed crash






Among the top winners and losers in the healthcare sector last week, the following four were standouts and bear watching or acting upon, depending, as always, on one’s risk tolerance…. Read more »

Novartis teams up with Allergan in NASH gamble; heated race to riches in full swing






The News: Allergan PLC (Dublin IRL) is expanding its research and development program on non-alcoholic steatohepatitis (NASH) through a collaboration with Novartis AG (Basel CHE) that will test a new… Read more »

Healthcare stocks have rough week as TherapeuticsMD, NantHealth fall flat; but Neurocrine, Tocagen shine






TherapeuticsMD Inc.(NYSE: TXMD) led a large contingent of stocks performing faceplants among the healthcare ranks. The clinical-stage biotech company focused on women’s health, plummeted $2.19, or 28%, to $7.70 in… Read more »

OncoMed rocked by combo punch as cancer trial bombs and Bayer walks; CEO not about to raise white flag






The News: OncoMed Pharmaceuticals Inc. (Redwood City CA) began the week with a combination punch that some say spells a knockout in the near future. In back-to-back statements, OncoMed revealed… Read more »

Wall Street cheers as Axovant snags biotech star David Hung; failed Alzheimer’s drug not impressed






The News: Axovant Sciences Ltd. (Hamilton Bermuda) announced that former Medivation Inc. (San Francisco) chief executive and founder David Hung has been selected as its next CEO effective April 7, 2017 sending… Read more »

Week’s opening stock roundup: gainers include Novocure, Steadymed; but Corvus, NewLink rocked






Here to start your trading week are the major movers from last week and where they stand this morning: Novocure (Nasdaq: NVCR) led advancing issues, soaring $3.25, or 40% over the… Read more »

Mylan’s EpiPen profitable despite recalls, lawsuits; stock price immune to ethics rants






Mylan NV (Amsterdam) is facing a new class-action lawsuit related to the price hikes of it EpiPen devices. The lawsuit was filed in federal court in Tacoma, Washington on Monday… Read more »